We evaluated the outcome of 63 children given haematopoietic stem cell transplantation from unrelated donors (URD-HSCT) prospectively selected using DNA highresolution typing of both HLA class I and class II loci. Thirty patient/donor pairs (48%) were fully matched. Among the others, HSCT was performed in the presence of one (n ¼ 22), two (n ¼ 9), or three (n ¼ 2) HLA disparities. Patients had either malignant (n ¼ 46) or non-malignant (n ¼ 17) disease. In all cases, graft-versushost disease (GVHD) prophylaxis consisted of cyclosporin A, short-term methotrexate and pretransplant antithymocyte globulin. The probability of haematopoietic recovery at day 100 was 97%. Two patients experienced primary graft failure. The cumulative probability of grades III-IV acute GVHD and of extensive chronic GVHD equalled 8 and 14%, respectively. A total of 12 patients died of transplant-related complications. The probability of transplant-related mortality (TRM) at 100 and 180 days was 10 and 15%, respectively, whereas the cumulative incidence of TRM was 22%. The probability of GVHD-related mortality equalled 6% at 2.5 years. The overall and disease-free survival rates were 67 and 65%, respectively. URD-HSCT with donor selection based on high-resolution HLA typing is associated with low incidence of both severe acute GVHD and graft failure. The observed outcome is comparable to that of children transplanted from HLA-identical siblings.
GVHD; graft failure; transplant-related mortality Although haematopoietic stem cell transplantation from an unrelated donor (URD-HSCT) is an accepted mode of treatment for patients with haematological disorders, a higher risk of transplant-related mortality (TRM) has been reported when compared with transplantation from HLAidentical siblings. 1, 2 The difference is, at least partially, because of HLA disparities between the patient and the unrelated donor, sometimes not revealed because of the limits of serological or low-resolution molecular typing of HLA loci. These disparities, in turn, contribute to increased incidence of severe graft-versus-host disease (GVHD) and graft rejection, two major obstacles for successful allogeneic HSCT. [3] [4] [5] [6] Thus, adequate HLA matching seems to be essential to improve the outcome of URD-HSCT, and the results of such transplants must be assessed with consideration to the typing method used to select the most suitable donor.
Until recently, HLA matching was performed employing serological techniques for HLA-A and -B loci, and highresolution molecular typing for HLA-DRB1 alleles. Several studies clearly demonstrated that among serologically matched unrelated patient/donor pairs a high level of HLA class I incompatibility can be detected when DNAbased typing is applied. [7] [8] [9] . Moreover, among HLA-A, -B, and -DR allele-matched pairs, 25% remained incompatible for HLA-C. 10 Efforts have been made to reveal whether HLA class I allele disparity has an impact on clinical outcome. For this purpose, investigators retyped patient and donor samples and analysed the outcome retrospectively. The recently updated study by the Japan Marrow Donor Program (JMDP) showed that all HLA-A, -B, and -C mismatches resulted in an increased risk of grades III-IV acute GVHD. HLA-A and -B, but not HLA-C disparity, were associated with decreased survival. 11, 12 On the other hand, the analysis by the Seattle group demonstrated that multiple HLA class I and/or class II mismatches were associated with increased mortality, whereas patients transplanted with a single antigendisparate donor had an outcome comparable to that of subjects given a fully matched transplant. 13 Two further studies including smaller number of patients demonstrated that the presence of any mismatch for HLA class I or class II alleles was associated with decreased probability of survival, compared with fully matched patient/donor pairs. 14, 15 Taken together, all the above findings provided the rationale for introduction of high-resolution HLA class I molecular typing as a routine method in the process of unrelated donor selection.
In this study, for the first time, we assess the outcome of URD-HSCT in paediatric patients for whom the donor was prospectively selected using high-resolution DNA typing for both HLA class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) loci. In the two participating centres this strategy has been adopted since 1999. Our analysis mainly focused on the occurrence of both acute GVHD and graft failure (primary objectives). Chronic GVHD, TRM, GVHD-related mortality (GVHD-RM), overall survival (OS) and event-free survival (EFS) were also analysed, together with the potential influence of HLA incompatibility on outcome.
Patients and methods

Patients
In all, 63 consecutive patients aged o18 years treated with URD-HSCT between September 1999 and February 2002 were included in the study. The transplant procedures were performed in two HSCT centres: the Department of Paediatric Haematology Oncology, IRCCS Policlinico San Matteo, Pavia, Italy (n ¼ 58) and the Department of Haematology and BMT, Silesian Medical Academy, Katowice, Poland (n ¼ 5). All the donors were prospectively selected using DNA high-resolution typing for both HLA class I and class II loci. The median age of the 41 male and 22 female patients was 8 years (range 5 months-18 years), whereas the median donor age was 35 years (range 20-54 years). Indications for URD-HSCT were malignant (n ¼ 46) and nonmalignant (n ¼ 17) diseases. Among patients with either acute leukaemia or myelodysplastic syndrome, 15/39 (38%) procedures were performed on children who were not in complete haemato-logical remission. Details on patient and donor characteristics are reported in Table 1 . The 63 patients included into this analysis represent 58% of children who started the search for finding a suitable URD in the study period.
HLA typing and matching
Unrelated donors were located through a network of national and international bone marrow donor registries as previously described. 16 In all cases, HLA class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) loci were identified by polymerase chain reaction-single strand polymorphism (Dynal, Oslo, Norway) and sequence-based typing as previously described. 17 In all, 30 patient/donor pairs (48%) were considered fully compatible (10 out of 10 alleles matched). Among the other patients for whom a fully matched unrelated donor could not have been found, HSCT was performed despite the presence of one (n ¼ 22, 35%), two (n ¼ 9, 14%), or three (n ¼ 2, 3%) HLA antigen/ allele disparities. In 15 out of the 33 mismatched patient/ donor pairs, the incompatibility was restricted to HLA-C locus. Disparities in the GVHD direction (recipient's antigen/allele not shared by the donor) were present in 29/63 patients, disparities in the graft failure direction (donor's antigen/allele not shared by the recipient) were found in 30/63 patients ( Table 2 ). All patients but one were transplanted from a donor matched at the DRB1 loci.
As shown in Table 2 , if serological methods were applied, 37/63 (59%) patient/donor pairs would be considered fully compatible and only two out of eleven multiple mismatches would be identified.
URD-HSCT procedure
Bone marrow was used as a source of haematopoietic stem cells in 59 patients, whereas granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood were transplanted in four cases. In patients given a transplant of bone marrow stem cells, the median nucleated cell (NC) dose was 5.5 Â 10 8 /kg. In all, 22 patients (35%) were given a total-body irradiation-based preparative regimen, while the remaining 41 patients (65%) received a conditioning regimen consisting of chemotherapy alone:
Prophylaxis of GVHD was the same for all patients and consisted of cyclosporin, short-term methotrexate and pretransplant antithymocyte globulin (ATG, 7-11 mg/kg from days À4 to 2). Methylprednisolone was used as the first-line therapy of acute GVHD. In case of steroidresistance either extracorporeal phototherapy or ATG were introduced. 18 Out of the 63 patients, 54 were given recombinant human G-CSF after transplantation: it was administered usually starting from day 7 after URD-HSCT until neutrophil recovery (41 Â 10 9 /l). Cytomegalovirus (CMV) serological status was studied before transplantation in all donor/ recipient pairs (Table 1) . In all patients, the expression of pp65 human CMV matrix protein (antigenaemia) was monitored in order to detect CMV reactivation. Patients experiencing reactivation of CMV infection were treated according to a strategy of pre-emptive therapy with either ganciclovir or foscarnet at conventional dosage until antigenemia became negative. 19 
Definitions
Acute GVHD was diagnosed and graded according to previously reported criteria. 20 All patients surviving more than 7 days after transplant were considered at risk for developing acute GVHD. Children alive 80 days posttransplant with sustained donor engraftment were considered to be evaluable for chronic GVHD, which was classified as previously described. 21 Myeloid engraftment was defined as the first of three consecutive days with absolute neutrophil count (ANC) 40.5 Â 10 9 /l and platelet engraftment as the first of seven consecutive days with an unsupported platelet count (PLT) 450 Â 10 9 /l. Graft failure occurred if ANC did not rise within 28 days after URD-HSCT or declined below 0.2 Â 10 9 /l in patients in remission after initial recovery. The rate of graft failure was defined as (100 ÀANC engraftment rate (%)) at day 100 after transplantation.
TRM was defined as all causes of death without evidence of initial disease. GVHD-RM was defined as death caused by either acute or chronic GVHD. OS was the time between transplantation and death due to any cause, whereas EFS was defined as time interval from HSCT to the first event (either relapse or death in complete remission whichever occurred first).
Statistical analysis
The primary end points of this study were the incidence of graft failure and acute GVHD. The incidence of chronic GVHD, TRM, GVHD-RM, ANC, and PLT recovery, OS and EFS were the secondary end points.
The probabilities of acute and chronic GVHD, TRM, GVHD-RM, ANC, and PLT recovery were calculated as cumulative incidence, whereas OS and EFS were estimated using Kaplan-Meier method. 22 Patients who underwent a second transplant were censored for the first transplant at the date of second HSCT. The following factors were tested for their potential influence on the outcome: patient/donor HLA compatibility (fully matched vs single mismatch vs multiple mismatch), disparities for particular HLA loci: HLA-A, -B, -C, -DQB1, patient and donor age, patient and donor sex, CMV status, type of disease (malignant vs nonmalignant), type of conditioning (TBI vs chemotherapy based), cell dose. For continuous variables the median was taken as a cut point. The groups were compared using logrank test. A P-value o0.5 was considered statistically significant. Follow-up ended with either death or on 10 May 2002. Median survivor observation time equalled 15 months (range 3-31 months).
Results
Engraftment
Two patients experienced primary graft failure after URD-HSCT (probability =3%). One patient died, another was given a second transplant from the same donor, using peripheral blood as a source of stem cells, and finally (14) 10 ( engrafted. Both patients who failed to engraft received bone marrow from HLA-C mismatched donor and the NC dose infused was below median (2.5 Â 10 8 /kg and 4.2 Â 10 8 / kg). The probability of haematopoietic recovery at day 100 equalled 97% for ANC and 88% for PLT. Median time to reach neutrophil and platelet recovery was 17 and 26 days, respectively. Myeloid recovery after URD-HSCT was faster for patients receiving a NC dose higher than the median, that is, 45.5 Â 10 8 /kg (15 vs 18 days, P ¼ 0.047).
Graft-versus-host disease
Five patients developed grades III-IV acute GVHD and the cumulative probability of developing this complication at day 100 equalled 8%. The cumulative probability of grades II-IV acute GVHD was 40% (Figure 1) . One patient died of acute GVHD. The others responded to either first-or second-line therapy. Among the five patients who developed grades III-IV acute GVHD, two children were transplanted from a donor mismatched for HLA-C allele and one from a donor incompatible for both HLA-B and -C alleles.
The overall probability to develop chronic GVHD was 30% at 2.5 years. For the extensive form of chronic GVHD the incidence equalled 14% and tended to be higher in the presence of HLA-C mismatch (22 vs 10%) or HLA-DQB1 mismatch (33 vs 13%). However, the differences were not statistically significant. Two patients died of chronic GVHD at 4 and 12 months after transplantation, respectively.
Considering both acute and chronic GVHD, the probability of GVHD-RM at 2.5 years equalled 6% (Figure 2) .
Details on acute and chronic GVHD according to HLA matching are reported in Table 3 .
Transplant-related mortality
In all, 12 patients died of transplant-related complications. The probability of TRM at days 100 and 180 after transplantation were 10 and 15%, respectively, whereas the overall probability of TRM equalled 22%. The plateau was obtained after 1 year (Figure 2 ). The causes of TRM were as follows: interstitial pneumonitis (n ¼ 4), chronic GVHD (n ¼ 2), acute GVHD (n ¼ 1), graft failure (n ¼ 1), bacterial infection during neutropenia (n ¼ 1), acute respiratory distress syndrome (n ¼ 1), thrombotic thrombocytopenic purpura (n ¼ 1), EBV-related lymphopro liferative disease (n ¼ 1).
None of the potential prognostic factors was found to contribute to the incidence of TRM. In detail, the overall probabilities of TRM for patients transplanted from either a fully matched, a 1-antigen/allele-disparate donor or from an unrelated volunteer with multiple mismatches were not significantly different (see also Table 3 for details).
Survival
The Kaplan-Meier estimates of OS and EFS at 2.5 years were 67 and 65%, respectively (Figure 3 ). The probability of EFS was higher for patients with nonmalignant vs malignant disease (75 vs 60%), although the difference did not reach statistical significance. For acute leukaemia patients disease status at URD-HSCT tended to influence post-transplant outcome, patients given transplantation in complete remission having an EFS of 52% compared with 33% (P ¼ 0.1) for those transplanted without being in remission.
Discussion
Our study provides the first evaluation of patients for whom donor search and selection was based prospectively on high-resolution typing for both HLA class I and class II loci. The incidence of grade III and grade IV acute GVHD in our group was exceptionally low (8%). Moreover, only one patient died of acute GVHD. This finding together with the low incidence of graft failure (3%) translated into a low probability of early (before day 100) (10%) and overall (22%) TRM, which was more frequently associated with the toxicity of myeloablative therapy than with immunological complications. These results favourably compare with those obtained in our institutions in a cohort of 60 consecutive patients with similar clinical characteristics transplanted between January 1992 and December 1998, in whom the donor was selected on the basis of high- acute GVHD grade II-IV: 40% (s.e.+/-6%) Figure 1 Cumulative incidence estimates for the probability of acute GVHD grades II-IV and acute GVHD grades III-IV. In parenthesess.e.'s. Transplant-related mortality GVHD-related mortality: 6% (s.e. +/-3%) 0 100 200 300 400 500 Days 600 700 800 900 1000 Figure 2 Cumulative incidence estimates for the probability of transplant-related mortality (TRM) and GVHD-related mortality (GVHD-RM). In parentheses -s.e.'s.
resolution molecular typing for only HLA-class II loci. As presented in Table 4 , the cumulative probability of grades III-IV acute GVHD was significantly higher in that historical control compared with the present study group, and this translated into higher TRM rate, as well as higher GVHD-RM rate.
In the recently published study by the National Marrow Donor Program analysing 363 children with acute lymphoblastic leukaemia in second complete remission, the probability of grades III-IV acute GVHD equalled 29% with a TRM rate of 42%. 23 Smith et al 24 reported the outcome of 46 patients with juvenile myelomonocytic leukaemia who underwent URD-HSCT. 24 In that study, the probability of grades II-IV acute GVHD was 73%. Within 69 patients with Fanconi's anaemia reported by the European Group for Blood and Marrow Transplantation, 34% developed grade III or grade IV acute GVHD. 25 In all the above studies, serological typing of HLA class I antigens was used for donor selection. In this context, the introduction of DNA high-resolution typing for both HLA class I and class II alleles seems to be an important factor contributing to reduction of immunological complications in children undergoing URD-HSCT. Support to this interpretation is provided by the observation that the probability of grades III-IV acute GVHD of our patients is comparable to that reported in unicentre studies of T-celldepleted URD allograft for children with leukaemia in whom typing of HLA class I loci was performed using serological typing. 26, 27 With more accurate HLA matching, the probability to find a fully compatible unrelated donor is decreased. 28 This means that, in a proportion of patients who are in need of URD-HSCT, some level of incompatibility must be accepted. In our study, approximately half of the children were given transplant despite the presence of HLA disparity with the donor. In most cases, however, the incompatibility was restricted to only one locus and regarded usually HLA-C. The clinical relevance of such kind of disparity remains controversial. In our study, we did not find any correlation between the presence of HLA incompatibility in the donor/recipient pairs and the outcome. This, however, could be related to the limited number of subjects and events.
In a cohort of 300 patients, Petersdorf et al 13 demonstrated that a single HLA mismatch did not influence the incidence of both severe acute GVHD and mortality. On the other hand, HLA-C disparity was found to increase the risk of graft failure. 5 Graft failure, however, was shown to be strongly dependent on the NC dose, as well as on the recipient age, both factors being in favour of paediatric patients. 29 This advantage may overcome the HLA incompatibility-related risk of graft failure.
In opposition to the Seattle group, the JMDP study 11 including 1298 patient/donor pairs demonstrated that: (i) even a single mismatch for an HLA-A, -B, -C or -DR locus correlated with incidence of severe acute GVHD; (ii) HLA-A and/or HLA-B mismatch resulted in higher incidence of chronic GVHD, and (iii) any HLA class I disparity was associated with increased risk of graft failure. HLA-A or -B but not HLA-C incompatibility was found to negatively influence survival. 11 It has been hypothesised that HLA-Crelated acute GVHD may have diverse biological background and depends on the activity of NK cells rather than T lymphocytes. This, in turn, could translate into better response to immunosuppressive therapy. Extrapolation of the results obtained on the Japanese population to the Caucasians may not, however, be appropriate. Considerable differences were found between the genotypes of the two populations. The ethnic background may play a role, since it has been proven that the induction of acute GVHD depends on the amino-acid substitutions at particular positions of the HLA class I heavy chain. 30 All the patients treated in the Seattle study and the majority of patients in the JMDP study were not given pretransplant ATG. In contrast, in our study group, ATG Disease-free survival; 65% (s.e. +/-6%) Figure 3 Kaplan-Meier estimates for the probability of overall survival (OS) and disease-free survival (DFS). In parentheses -s.e.'s. Data are presented as cumulative probability at 2.5 years (%)7s.e.'s.
HLA high-resolution molecular typing for MUD-HSCT S Giebel et al was part of GVHD prophylaxis in all cases. This difference seems to be important, since ATG has recently been proven to reduce the incidence of both acute and chronic GVHD in a dose-dependent manner. 31 This kind of serotherapy leading to a depletion and modulation of function of donor T cells may be essential for overcoming the risk of immunological complications related to HLA incompatibility between donor and recipient.
In conclusion, donor selection based on high-resolution DNA typing for both HLA class I and class II loci seems to improve the outcome of patients undergoing URD-HSCT. Using this approach for donor selection and including ATG as part of GVHD prophylaxis, the risk of immunological complications, as well as TRM, is similar to that observed after transplant from a genotypically identical sibling. If a perfectly matched donor is not available, the presence of a single or even double mismatch is acceptable and does not seem to influence the outcome in paediatric patients. In such a case, however, risk-adapted modification of immunosuppressive therapy could be considered.
Further efforts should be focused on distinguishing permissible from nonpermissible mismatches, as well as on the evaluation of the role played by minor histocompatibility antigens reported to influence the risk of GVHD in some retrospective analyses. 17, 32, 33 Both issues could be achieved by the use of functional assays. In this regard, promising results have been obtained with the use of the skin explant model, 34 whereas the frequency of alloreactive cytotoxic T-lymphocyte precursors, found to correlate with the incidence of acute GVHD in adults, 35 was not proved to be useful in paediatric patients. 36 Finally, further large retrospective analyses may provide information concerning the significance of particular mismatches and related amino-acid substitutions in the HLA heavy chain.
